MedTrace Logo

Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

NCT01756508 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2018-08-31

No results posted yet for this study

Summary

Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.

Conditions

Interventions

DRUG

eculizumab

Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion

Sponsors & Collaborators

  • Russian Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Michael M Kaabak, MD · Russian Scientific Center of Surgery

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-01
Primary Completion
2017-04-15
Completion
2017-12-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01756508 on ClinicalTrials.gov